跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 115,930 条关于
“HR+/HER2- advanced breast cancer”
全部
115,930
临床试验
90,300
药物
2,703
机构
1,316
资讯
21,611
6个月前
Sihuan Pharmaceutical's Bireociclib Receives NMPA Approval for First-Line HR+/HER2- Advanced Breast Cancer Treatment
去年
Genentech's Inavolisib Receives FDA Approval for Advanced HR+, HER2- Breast Cancer
去年
Gedatolisib Shows Promising 77-Month Overall Survival in Advanced Breast Cancer Phase 1b Trial
2年前
MEDSIR Presents Promising Results in Breast and Thymic Cancer Trials at ESMO
去年
Celcuity Secures $500 Million Credit Facility Following Positive Phase 3 Data for Gedatolisib in Advanced Breast Cancer
去年
RLY-2608 Shows Promise in PI3Kα-Mutated HR+/HER2- Breast Cancer
11个月前
Phase 1 Trial Establishes Bireociclib as Promising CDK4/6 Inhibitor for Advanced Breast Cancer Treatment
去年
Celcuity Secures Patent Extension for Gedatolisib Through 2042, Strengthening Breast Cancer Drug Portfolio
去年
Genor Biopharma Secures NMPA Approval for Lerociclib CDK4/6 Inhibitor in Advanced Breast Cancer
去年
Lerociclib Plus Fulvestrant Shows Promise in HR+/HER2- Advanced Breast Cancer
第 1 页，共 2162 页
上一页
下一页
